| Pomalidomide studied in …STUDIED_INderived200 of 238show all (up to 200) |
|---|
| → studied in | NCT07222761Phase 3 · recruiting A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391657Phase 3 · recruiting A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181827Phase 3 · active not recruiting A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04577755Phase 2 · active not recruiting Pomalidomide Treatment in Patients With Kaposi Sarcoma · 238 trials list this drug (97 active) | — | — | Skin Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973605Phase 1/Phase 2 · recruiting A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05288062Phase 2 · terminated Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948084Phase 2 · recruiting Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01745588Phase 2 · completed Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108195Phase 1 · active not recruiting A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438043Phase 3 · active not recruiting A Study of Daratumumab · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455320Phase 3 · active not recruiting A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06768489Phase 1 · recruiting A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789303Phase 2 · recruiting Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661137Phase 2 · recruiting A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07096778Phase 2 · recruiting Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831122Phase 1 · not yet recruiting Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04902443Phase 1 · recruiting Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV · 238 trials list this drug (97 active) | — | — | Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04910568Phase 1 · recruiting A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623798Phase 3 · recruiting A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825064Phase 2 · recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883242Phase 2 · active not recruiting Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06615479Phase 3 · recruiting A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06953960Phase 1/Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555938Phase 3 · recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04124497Phase 2 · active not recruiting A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05519085Phase 3 · recruiting A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05208307Phase 2 · recruiting Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05405166Phase 3 · active not recruiting SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02659930Phase 1 · active not recruiting Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma · 238 trials list this drug (97 active) | — | — | Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06158841Phase 3 · active not recruiting Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · 238 trials list this drug (97 active) | — | — | B-Cell Neoplasm,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227311Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020236Phase 3 · recruiting A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06152575Phase 3 · recruiting MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05714839Phase 1/Phase 2 · recruiting A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06106945Phase 1/Phase 2 · recruiting AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05259839Phase 1 · active not recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07463807Phase 1/Phase 2 · recruiting Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07760610Phase 4 · not yet recruiting Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response · 238 trials list this drug (97 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748689Phase 2 · not yet recruiting Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05669989Phase 2 · enrolling by invitation International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04458831completed A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06413498Phase 3 · active not recruiting A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07728188Phase 3 · not yet recruiting A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07720843Phase 1 · not yet recruiting TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05556798Phase 1 · active not recruiting A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07532525Phase 1 · recruiting Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma · 238 trials list this drug (97 active) | — | — | B-Cell Non-Hodgkin Lymphoma,B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451771Phase 1/Phase 2 · active not recruiting Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis · 238 trials list this drug (97 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06508983Phase 3 · recruiting A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137054Phase 1 · recruiting A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04850599Phase 2 · active not recruiting Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802161Phase 2 · active not recruiting Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes · 238 trials list this drug (97 active) | — | — | Myelodysplastic Syndrome,Myeloproliferative Neoplasm,Acute Myeloid Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562405Phase 1 · active not recruiting Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150104Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068597Phase 1/Phase 2 · recruiting Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · 238 trials list this drug (97 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637526not yet recruiting Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03651128Phase 3 · completed Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04643002Phase 1/Phase 2 · recruiting Isatuximab in Combination With Novel Agents in RRMM - Master Protocol · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01946477Phase 2 · completed Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04484623Phase 3 · active not recruiting Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06956170Phase 3 · active not recruiting All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05911321Phase 2 · active not recruiting Isa-Pom-Dex in Elderly/Frail Subjects With RRMM · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04176718Phase 2 · active not recruiting Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07018050Phase 2 · recruiting Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04508790Phase 2 · recruiting Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609446not yet recruiting Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma · 238 trials list this drug (97 active) | — | — | Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07138209Phase 3 · recruiting A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04302324Phase 2 · active not recruiting A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01053949Phase 2 · completed IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07569757Phase 3 · not yet recruiting Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126200Phase 1/Phase 2 · active not recruiting Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07560449Phase 2 · not yet recruiting QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02719613Phase 2 · completed Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07523737Phase 2 · recruiting Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma · 238 trials list this drug (97 active) | — | — | Primary Central Nervous System Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601806Phase 2 · completed Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection · 238 trials list this drug (97 active) | — | — | Skin Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04667663Phase 1 · active not recruiting CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572515Phase 3 · active not recruiting A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984097Phase 1 · completed A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925193Phase 2 · active not recruiting Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835129Phase 2 · active not recruiting Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07452198Phase 3 · recruiting A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05730036Phase 3 · recruiting A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04094961Phase 1/Phase 2 · active not recruiting Ixazomib + Pomalidomide + Dexamethasone In MM · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04270175Phase 2 · active not recruiting Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab · 238 trials list this drug (97 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04764942Phase 1/Phase 2 · active not recruiting Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01745640Phase 2 · completed Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05556616Phase 1 · terminated A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02718833Phase 2 · active not recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04392648Phase 1 · withdrawn A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05922501Phase 2 · recruiting Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Malignant Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03030261Phase 2 · active not recruiting Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01665794Phase 1/Phase 2 · completed Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03180736Phase 3 · completed Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05028348Phase 3 · active not recruiting A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07257510NA · recruiting Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma · 238 trials list this drug (97 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01592370Phase 1/Phase 2 · completed An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Hodgkin Lymphoma,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03590652Phase 2 · terminated Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03287908Phase 1 · terminated A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03731832Phase 2 · completed Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04045795Phase 1 · completed Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01198067Phase 1 · terminated Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia · 238 trials list this drug (97 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191616Phase 2 · completed Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03828292Phase 1 · completed An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06464991Phase 3 · recruiting A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03713294Phase 2 · completed Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03539744Phase 3 · active not recruiting A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07015021NA · not yet recruiting The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892446Phase 2 · terminated Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03756896Phase 2 · active not recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01998971Phase 1 · completed A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03288974completed Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02555839completed Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04700176Phase 2 · terminated A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02990338Phase 3 · completed Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06342466Phase 2 · recruiting Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03582033Phase 1 · terminated A Safety Study of SEA-BCMA in Patients With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06742138Phase 3 · not yet recruiting To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02406222Phase 2 · active not recruiting Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02939183Phase 1 · completed Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02542657Phase 1/Phase 2 · active not recruiting Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02616640Phase 1 · completed A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06554561Phase 1/Phase 2 · recruiting A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma · 238 trials list this drug (97 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050305Phase 2 · withdrawn Marizomib Central Nervous System (CNS) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02400242Phase 1 · terminated Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06455748NA · unknown Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06232707Phase 3 · withdrawn A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03143985Phase 1 · completed Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06376214NA · recruiting Daratumumab for Patients With Light Chain Amyloidosis · 238 trials list this drug (97 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03257631Phase 2 · completed A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors · 238 trials list this drug (97 active) | — | — | Central Nervous System Neoplasm,Medulloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02119468Phase 1/Phase 2 · completed Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01754402Phase 1/Phase 2 · unknown Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03151811Phase 3 · terminated A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02004275Phase 1/Phase 2 · unknown Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02294357Phase 2 · terminated Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02206425Phase 1/Phase 2 · completed Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02547662Phase 2 · completed Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia · 238 trials list this drug (97 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia,Plasmacytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04843579Phase 2 · terminated Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05378971NA · unknown Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03202628Phase 2 · completed Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05205252Phase 1/Phase 2 · withdrawn A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · 238 trials list this drug (97 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959358Phase 2 · completed A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders · 238 trials list this drug (97 active) | — | — | Multiple Myeloma,Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02185820Phase 1/Phase 2 · completed Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01734928Phase 3 · completed Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01728259Phase 1 · terminated First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD · 238 trials list this drug (97 active) | — | — | Light Chain Deposition Disease,Primary Systemic Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05809180NA · unknown Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients · 238 trials list this drug (97 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02726581Phase 3 · completed An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895410Phase 1 · terminated Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04941937Phase 2 · unknown Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03439280Phase 1/Phase 2 · completed A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02807454Phase 2 · terminated A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05432414Phase 2 · unknown PVd Versus Vd in NDMM Patients With RI · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05408026Phase 1/Phase 2 · withdrawn Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04287855Phase 2 · unknown Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03798314Phase 1 · completed Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03170882Phase 2 · completed A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01495598Phase 1/Phase 2 · completed Pomalidomide for Kaposi Sarcoma in People With or Without HIV · 238 trials list this drug (97 active) | — | — | Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02654132Phase 2 · completed An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02164955completed A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma. · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581875Phase 1/Phase 2 · not yet recruiting A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory · 238 trials list this drug (97 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05509374Phase 2 · unknown Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01464034Phase 1/Phase 2 · terminated A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03841565Phase 2 · withdrawn Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05390749Phase 2 · unknown Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL · 238 trials list this drug (97 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05183139Phase 4 · withdrawn A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02415153Phase 1 · completed Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors · 238 trials list this drug (97 active) | — | — | Primary Central Nervous System Neoplasm,Childhood Brain Stem Glioma,Childhood Visual Pathway Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03104270Phase 2 · terminated Combination Study for High Risk Multiple Myeloma Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113942Phase 2 · unknown Study of Pomalidomide in Anal Cancer Precursors · 238 trials list this drug (97 active) | — | — | High Grade Squamous Intraepithelial Neoplasia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05298683Phase 2 · unknown A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor · 238 trials list this drug (97 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05236621Phase 3 · unknown A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01712789Phase 3 · completed Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01421186Phase 1/Phase 2 · completed A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02576977Phase 3 · terminated Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04584307Phase 2 · withdrawn Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01946152Phase 1/Phase 2 · terminated Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02283775Phase 1 · completed SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02612779Phase 2 · completed A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03567616Phase 2 · terminated A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02569320Phase 1 · completed HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03520985Phase 2 · terminated Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01999335Phase 1 · terminated A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01177735Phase 2 · completed Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02431208Phase 1 · completed A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440411Phase 3 · terminated Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762745Phase 1/Phase 2 · unknown The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02029950Phase 1 · completed Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · 238 trials list this drug (97 active) | — | — | Myeloproliferative Neoplasm,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia-2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01570387Phase 1/Phase 2 · completed A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis · 238 trials list this drug (97 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04355039Phase 1 · withdrawn INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01212952Phase 1/Phase 2 · completed Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02265510Phase 1/Phase 2 · terminated An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies · 238 trials list this drug (97 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01497093Phase 1 · completed Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03242460Phase 2 · completed The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) · 238 trials list this drug (97 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00669578Phase 1/Phase 2 · completed CC-4047 in Treating Patients With Myelofibrosis · 238 trials list this drug (97 active) | — | — | Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02548962Phase 1/Phase 2 · terminated Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma · 238 trials list this drug (97 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00463385Phase 2 · completed A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia · 238 trials list this drug (97 active) | — | — | Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00537511Phase 1/Phase 2 · terminated A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide · 238 trials list this drug (97 active) | — | — | Small Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |